Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.
|Articles|October 1, 2004
Putting recommendations for influenza into (real-world) practice
Concerned about the logistics of vaccinating patients this flu season, now that even healthy children younger than 2 years are to be immunized? Worried about reimbursement? For a practical approach to vaccinating against influenza--without putting a financial strain on your practice--read on.
Advertisement
Advertisement
Related to this article
Hai D. Nguyen-Tran, MD, discusses clinical signs, neurologic warning symptoms, supportive care, and preventing the spread of hand, foot, and mouth disease.
Diana F. Clarke, PharmD, explains how IMPAACT 2023 supported dolutegravir from birth, plus dosing tips and open questions for preterm infants.
An updated AAP policy statement renews the call to ban raw milk sales, citing pathogen risks to children and pregnant people and an emerging H5N1 concern.
At AAP 2026, Rana Hamdy, MD, discussed when to test children for group A strep, antibiotic selection, and strategies to improve prescribing.
Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
The latest IDSA histoplasmosis update adds a consensus statement on severe disease and outlines when children with pulmonary infection warrant itraconazole therapy.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Hand, foot, and mouth disease: Red flags pediatricians should know
2
FDA approval of Gazyva offers new option for pediatric INS
3
DTaP 96% effective against pertussis in Alaska outbreak
4
FDA grants Cinainu Breakthrough Therapy status for pediatric AA
5